1![1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni 1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni](https://www.pdfsearch.io/img/0e10d9a50ca577cafbe84d1bb17f5b37.jpg) | Add to Reading ListSource URL: static.coreapps.net- Date: 2016-10-12 15:43:04
|
---|
2![présenteit - mediA - phA rmA présenteit - mediA - phA rmA](https://www.pdfsearch.io/img/a58849bda320cbbb143f1cbb6888bdde.jpg) | Add to Reading ListSource URL: www.icosa.frLanguage: English - Date: 2014-06-30 06:12:13
|
---|
3![Microsoft Word - GILEAD BRIEFING Microsoft Word - GILEAD BRIEFING](https://www.pdfsearch.io/img/3d23912ac22fcee606c517d8f35a0daf.jpg) | Add to Reading ListSource URL: www.ukts.orgLanguage: English - Date: 2016-07-02 14:50:25
|
---|
4![Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases](https://www.pdfsearch.io/img/b6f5edfd3c99a96e1fbe3bf9a6773b86.jpg) | Add to Reading ListSource URL: www.hepatitis-schweiz.chLanguage: English - Date: 2016-02-01 04:42:51
|
---|
5![Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl](https://www.pdfsearch.io/img/4c2afb0ad5bee725039d2521acd267a4.jpg) | Add to Reading ListSource URL: www.pmda.go.jpLanguage: English - Date: 2016-08-04 23:25:56
|
---|
6![--------------------------------CONTRAINDICATIONS----------------------------- EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN --------------------------------CONTRAINDICATIONS----------------------------- EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN](https://www.pdfsearch.io/img/763cd55ea5b173975689fd1ecab036b6.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2016-06-28 12:26:37
|
---|
7![GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations](https://www.pdfsearch.io/img/3a89d32c03df117a15a9ff1e87db97a8.jpg) | Add to Reading ListSource URL: www.gilead.comLanguage: English - Date: 2016-06-28 22:53:08
|
---|
8![Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl](https://www.pdfsearch.io/img/5e25dcd4ce32639e0077a9c235b2924a.jpg) | Add to Reading ListSource URL: www.pmda.go.jpLanguage: English - Date: 2016-08-04 23:25:54
|
---|
9![Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases](https://www.pdfsearch.io/img/51d0ecbad8c0d92d3c3efd58339f90d1.jpg) | Add to Reading ListSource URL: sasl.unibas.chLanguage: English - Date: 2016-01-13 10:08:24
|
---|
10![Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction](https://www.pdfsearch.io/img/64f6d0c87fa3afe60bf88e0567400ac0.jpg) | Add to Reading ListSource URL: www.easl.euLanguage: English - Date: 2015-09-08 13:26:17
|
---|